Vaccines for children
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75D30122D13474
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
CDC Pittsburgh
Centers for Disease Control and Prevention, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Vaccines for Children Solicitation · 75D30122R72134 · Posted Jan 7, 2022
- Last date to order 100% complete
- IDV ceiling
- $1,141,648,900.00
- Maximum order
- $1,141,648,900.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide up to 23 standard pediatric vaccines. The $1.14 billion, multiple-award contract has a period of performance from April 1, 2022 to March 31, 2023 and supports pediatric immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. The vaccines, which must have a minimum 12-month shelf life and be FDA-licensed, will be shipped FOB destination to the 50 states and territories. Quantities range from a minimum of 100 doses to a maximum of 13 million doses, depending on the vaccine type. This IDC was not set aside and does not indicate any evaluation criteria. The solicitation sought to establish multiple IDIQ contracts to purchase the required pediatric vaccines, which include common childhood immunizations such as DTaP, Hib, MMR, and Varicella.
Glaxosmithkline, an established pharmaceutical firm, has held other federal IDVs and contract awards with agencies like the Departments of Defense, Veterans Affairs, and Health and Human Services to provide a range of vaccines, antiviral medications, and other pharmaceutical products in support of disease prevention, drug stockpiling, and correctional facility healthcare services. This particular contract will help ensure adequate supply and distribution of essential pediatric vaccines to meet public health requirements nationwide.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | -$482 | |
| Funding Only Action | $58,980,072 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $8,683,079 | |
| Funding Only Action | $170,617,160 | |
| Funding Only Action | $125,454,778 | |
| Funding Only Action | $243,129,348 | |
| Original award | $257,420,725 |
Quick answers
Who was awarded contract 75D30122D13474?
75D30122D13474 was awarded to Glaxosmithkline, LLC by CDC Pittsburgh (Centers for Disease Control and Prevention) on April 1, 2022.
How much is contract 75D30122D13474 worth?
75D30122D13474's own ceiling is $1,141,648,900. A single order can be worth up to $1,141,648,900.
Who can order from contract 75D30122D13474?
75D30122D13474 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75D30122D13474 competed?
The extent of competition for 75D30122D13474 was full and open competition. The government received 5 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV